Therefore, a potential explanation for treatment failure in MS, as well as the adverse neurological events that occurred in other therapies, is the non-selective effect of TNF-α inhibitors currently in use, which counteracts the anti-inflammatory activity mediated by TNFR2 receptors. Here, TNF is linked to myeloid sarcoma.